

NOV. 26. 2004 3:24PM

GENAISANCE PHARM.

RECEIVED
CENTRAL FAX CENTER

NO. 049 P. 2

Appl. No.10/085,612
Amendment dated November 26, 2004
Reply to Office Action mailed November 12, 2004

NOV 26 2004

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-16. (canceled)

17.(currently amended) A method of screening an individual for predisposition for reduced metabolism of a CYP3A4 substrate or a CYP3A5 substrate , said method comprising: determining the presence or absence in the individual of one or both of a G at position -392 of the promoter of a CYP3A4 gene with respect to the start codon of said CYP3A4 gene; and a G at a position corresponding to nucleotide 1037 in SEQ ID NO:4; and identifying the individual as having a predisposition for reduced metabolism of the CYP3A4 substrate or the CYP3A5 substrate if one or both of the G at position -392 of the promoter of the CYP3A4 gene with respect to the start codon of the CYP3A4 gene is determined to be present in the individual; and identifying the individual as having a predisposition for reduced metabolism of the CYP3A5 substrate if the G at nucleotide 1037 in SEQ ID NO:4 is determined to be present in the individual.

18.(currently amended) The method of Claim 17, whereinsaid determining comprises, determining whether said individual is homozygous or heterozygous for one or both of the G at position -392 of the promoter of the CYP3A4 gene with respect to the start codon of the CYP3A4 gene and the G at a position corresponding to nucleotide 1037 in SEQ ID NO:4.

19.-21. (canceled)

App. No. 10/085,612
Amendment dated November 26, 2004
Reply to Office Action mailed November 12, 2004

22.(previously presented) The method of Claim 17, wherein the CYP3A4 substrate is a nitrogen mustard or BCNU and the CYP3A5 substrate is a nitrogen mustard or BCNU.

23.-24. (canceled)

25.(currently amended) A method for selecting a treatment for a cancer patient, said method comprising:

determining the presence or absence in the cancer patient of one or more of a G at position -392 of the promoter of a CYP3A4 gene with respect to the start codon of the CYP3A4 gene;

a G at a position corresponding to nucleotide 1037 in SEQ ID NO:4; and a GSTM1 null mutation; and

selecting a treatment selected from the group consisting of:

a treatment that does not comprise administration of an anti-cancer prodrug metabolized to the active drug by CYP3A4 or CYP3A5 if one or both of the G at position -392 of the promoter of the CYP3A4 gene with respect to the start codon of the CYP3A4 gene or the G at a position corresponding to nucleotide 1037 in SEQ ID NO:4. is determined to be present in the cancer patient;

a treatment that does not comprise administration of an anti-cancer prodrug metabolized to the active drug by CYP3A5 if the G at nucleotide 1037 in SEQ ID NO:4. is determined to be present in the cancer patient;

a treatment that comprises administration of an anti-cancer prodrug metabolized to the active drug by CYP3A4 or CYP3A5 if one or both of the G at position -392 of the promoter of the CYP3A4 gene with respect to the start codon of the CYP3A4 gene or the G at a position corresponding to nucleotide 1037 in SEQ ID NO:4. is determined to be absent in the cancer patient;

a treatment that comprises administration of an anti-cancer prodrug metabolized to the active drug by CYP3A5 if the G at nucleotide 1037 in SEQ ID NO:4. is determined to be absent in the cancer patient;

a treatment that does not comprise administration of an anticancer drug which is an alkylating agent metabolized by GSTM1 if the GSTM1 null mutation is determined to be absent in the cancer patient; and

Appl. No.10/085,612

Amendment dated November 26, 2004

Reply to Office Action mailed November 12, 2004

a treatment that comprises administration of an anticancer drug which is an alkylating agent metabolized by GSTM1 if the GSTM1 null mutation is determined to be present in the cancer patient. [[;]]

~~a treatment that comprises administration of a higher than conventional dose of an anti-cancer prodrug metabolized to the active drug by CYP3A4 or CYP3A5 if one or both of the G at position -392 of the promoter of the CYP3A4 gene with respect to the start codon of the CYP3A4 gene or the G at a position corresponding to nucleotide 1037 in SEQ ID NO:4, is determined to be present in the cancer patient;~~

~~a treatment that comprises administration of a conventional dose of an anti-cancer prodrug metabolized to the active drug by CYP3A4 or CYP3A5 if one or both of the G at position -392 of the promoter of the CYP3A4 gene with respect to the start codon of the CYP3A4 gene or the G at a position corresponding to nucleotide 1037 in SEQ ID NO:4, is determined to be absent in the cancer patient;~~

~~a treatment that comprises administration of a higher than conventional dose of an anticancer drug which is an alkylating agent metabolized by GSTM1 if the GSTM1 null mutation is determined to be absent in the cancer patient; and~~

~~a treatment that comprises administration of a conventional dose of an anticancer drug which is an alkylating agent metabolized by GSTM1 if the GSTM1 null mutation is determined to be present in the cancer patient.~~

26.(currently amended) The method of Claim 25, wherein said determining comprises, determining whether the cancer patient is homozygous or heterozygous for one or more of the G at position -392 of the promoter of the CYP3A4 gene with respect to the start codon of the CYP3A4 gene, the G at a position corresponding to nucleotide 1037 in SEQ ID NO:4, and the GSTM1 null mutation.

27.-29. (canceled)

30.-34. (canceled)

35. (previously presented) The method of claim 17, wherein the determining comprises obtaining a genomic DNA sample from the individual; and

Appl. No.10/085,612
Amendment dated November 26, 2004
Reply to Office Action mailed November 12, 2004

performing a PCR amplification reaction on the sample using one or both of PCR primer pairs (a) SEQ ID NO:17 and SEQ ID NO:18 or (b) SEQ ID NO:21 and SEQ ID NO:22.

36. (previously presented) The method of claim 22, wherein the CYP3A4 substrate is the nitrogen mustard and the CYP3A5 substrate is the nitrogen mustard.

37. (previously presented) The method of claim 36, wherein the nitrogen mustard is cyclophosphamide.

38. (previously presented) The method of claim 22, wherein the CYP3A4 substrate is BCNU and the CYP3A5 substrate is BCNU.

39. (previously presented) The method of 25, wherein the anti-cancer prodrug is a nitrogen mustard.

40. (previously presented) The method of 39, wherein the nitrogen mustard is cyclophosphamide.

41. (previously presented) The method of 25, wherein the alkylating agent is a nitrosourea, a nitrogen mustard or cisplatin.

42. (previously presented) The method of 41, wherein the nitrosourea is BCNU.

43. (previously presented) The method of claim 25, wherein the determining comprises obtaining a genomic DNA sample from the cancer patient; and performing a PCR amplification reaction on the sample using one or more of PCR primer pairs: (a) SEQ ID NO:17 and SEQ ID NO:18; (b) SEQ ID NO:21 and SEQ ID NO:22; or (c) SEQ ID NO:23 and SEQ ID NO:24.

44. (currently amended) The method of claim 25, the method comprising determining the presence or absence in the cancer patient of each of the G at position -392 of the promoter of a CYP3A4 gene with respect to the start codon of the CYP3A4 gene;

NOV. 26. 2004 3:25PM GENAISANCE PHARM.

NO. 049 P. 6

* Appl. No. 10/085,612

Amendment dated November 26, 2004

Reply to Office Action mailed November 12, 2004

the G at a position corresponding to nucleotide 1037 in SEQ ID NO:4; and
the GSTM1 null mutation.